Colorectal Cancer
Colorectal Cancer
Advertisement
Emily MenendezColorectal Cancer | December 4, 2024
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
Read More
Emily MenendezColorectal Cancer | December 3, 2024
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
Emily MenendezColorectal Cancer | November 9, 2024
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
Brandon TwyfordColorectal Cancer | September 19, 2024
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
Brandon TwyfordColorectal Cancer | September 16, 2024
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Zachary BessetteColorectal Cancer | September 13, 2024
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
Jordana JampelColorectal Cancer | September 12, 2024
Neoadjuvant nivolumab plus relatlimab led to a pathologic response rate of 96%.
Zachary BessetteColorectal Cancer | September 12, 2024
The CodeBreaK 101 study assessed the safety and efficacy of soto, pani, and FOLFIRI for KRAS G12C-mutated mCRC.
Brandon TwyfordColorectal Cancer | September 12, 2024
Cetuximab rechallenge guided by liquid biopsy improved response and disease control rates in RAS wild-type mCRC.
Jordana JampelColorectal Cancer | September 11, 2024
1L zanidatamab plus chemo with or without bevacizumab demonstrated antitumor activity and manageable safety in mCRC.
Zachary BessetteColorectal Cancer | September 11, 2024
The latest data from the RECAST trial shed light on FOLFIRI plus RAM for patients with metastatic CRC.
William M. Grady, MDColorectal Cancer | September 11, 2024
Dr. Grady opines on whether colonoscopy, stool-based, or blood-based tests will be integrated into CRC screening guidelines.
William M. Grady, MDColorectal Cancer | September 11, 2024
Dr. Grady discusses ECLIPSE for colorectal cancer screening and the findings that led to approval of the Shield test.
Christopher Lieu, MDColorectal Cancer | September 11, 2024
Dr. Lieu breaks down his top uses of AI in GI oncology today, as well as their projected applicability in the near future.
Katy MarshallColorectal Cancer | September 4, 2024
There is little research on the efficacy of adding oxaliplatin to treat older patients with the disease.
Katy MarshallColorectal Cancer | August 21, 2024
The systematic review included data from 12 randomized controlled trials, 2 systematic reviews, and 1 nonrandomized study.
Emily MenendezColorectal Cancer | August 15, 2024
Trastuzumab deruxtecan has provided encouraging activity for treatment-refractory HER2+ RAS and BRAF wild-type mCRC.
Katy MarshallColorectal Cancer | August 13, 2024
Investigators calculated the C-for-benefit to evaluate evidence for HTE.
Wafik El-Deiry, MD, PhD, FACPColorectal Cancer | August 19, 2024
Dr. El-Deiry expands on reducing ALDH1 expression in HT29 cells, and the benefits of targeting ERK1/2 and STAT3 activation.
Wafik El-Deiry, MD, PhD, FACPColorectal Cancer | August 19, 2024
Dr. Wafik El-Deiry of Brown University discusses his study on regorafenib with TAS-102 for colorectal cancer.
Advertisement
Advertisement
Advertisement
Latest News

December 11, 2024